

**Table 1.** Recommendations of the American Thyroid Association (ATA) and the European Thyroid Association (ETA) for long-term Thyroid Stimulating Hormone suppressive therapy for differentiated thyroid cancer

---

	<b>ATA</b>	<b>ETA</b>
Persistent disease including detectable serum Tg	<0.1 mU/l	≤0.1 mU/l
High risk with no evidence of disease	0.1-0.5 mU/l for 5-10 years	≤0.1 mU/l for 3-5 years
Low-risk patients with apparent cure on follow-up testing	0.3-2 mU/l	0.5-1 mU/l

---